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The lymphatic vasculature system is important for at 
least three functions; first, it controls the absorbance 
of nutrients including proteins and lipids from blood 
vasculature into peripheral tissues. Moreover, other 
small molecules such as cytokines and chemokines of 
interstitial fluids are transported through the lymphatic 
vessels. Second, lymphatic vessels are used as a route 
of immune cell trafficking from peripheral tissues into 
lymph nodes. Lymphocytes and dendritic cells that have 
encountered foreign antigens can access the lymphatic 
capillaries dependent on chemokine gradients (1,2). 
Lastly, the lymphatic vasculature system maintains the 
homeostasis of tissue fluid by regulating lymph transport. 
The lymph fluid drains into the thoracic lymphatic duct, 
then gets back into blood circulation (3). This lymphatic 
transport is tightly regulated by the osmotic gradients and 
fluid barrier filtration from cytokines, chemokine, and 
other macromolecules (2). Accordingly, individuals with 
abnormal lymph circulation or surgery to remove a lymph 
node can develop lymphedema with impaired immune 
responses. In this review, we demonstrate the general 
functions of the lymphatic vasculature system and then 
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The lymphatic vasculature has been regarded as a passive conduit for interstitial fluid and responsible for the 
absorption of macromolecules such as proteins or lipids and transport of nutrients from food. However, emerging 
data show that the lymphatic vasculature system plays an important role in immune modulation. One of its major 
roles is to coordinate antigen transport and immune-cell trafficking from peripheral tissues to secondary lymphoid 
organs, lymph nodes. This perspective was recently updated with the notion that the interaction between lymphatic 
endothelial cells and leukocytes controls the immune-cell migration and immune responses by regulating lymphatic 
flow and various secreted molecules such as chemokines and cytokines. In this review, we introduce the lymphatic 
vasculature networks and genetic transgenic models for research on the lymphatic vasculature system. Next, we 
discuss the contribution of lymphatic endothelial cells to the control of immune-cell trafficking and to maintenance 
of peripheral tolerance. Finally, the physiological roles and features of the lymphatic vasculature system are further 
discussed regarding inflammation-induced lymphangiogenesis in a pathological condition, especially in mucosal 
tissues such as the gastrointestinal tract and respiratory tract.
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discuss studies from the perspective that the lymphatic 
system is closely linked with the pathophysiology of 
inflammatory conditions and can control them. Especially, 
we focus on elucidation of how specialized lymphatic 
vasculature coordinates multiple physiological roles, 
how lymphatic vessels regulate immune cell trafficking, 
and how lymphatic vessels themselves respond to in-
flammation. 
lymPhaTICs IN The CIRCUlaTORy sysTem
In our body, the vascular circulatory system consists of 
blood and lymphatic vessels, both of which are lined by 
endothelial cells. Lymphatic vasculature is composed of a 
branched network of capillaries and collecting lymphatic 
vessels. Unlike blood vasculature, lymphatic capillaries 
are blind-ended and lack pericytes. As an open system, 
the ubiquitous network of lymphatic capillaries (10 to 
80 mm in diameter) and vessels transport interstitial fluid 
from the arterial ends of blood vessels back into the main 
circulatory system. Interstitial fluid enters the lymphatic 
system through single-layered lymph capillaries. The 
discontinuous basement membrane and weak cell-to-
cell attachments make the lymphatic capillaries highly 
permeable, thereby facilitating uptake of proteins 
including nutrients, viruses, and other large solutes, which 
in general have very low diffusivity (4). Unidirectional 
fluid flow from the capillaries toward the lymph nodes is 
regulated by lymphatic valves, which inhibit its backflow. 
The individual capillaries merge to form large lymphatic 
collecting vessels. The lymphatic collecting vessels are 
segmented into regions called lymphangions that are 
interconnected by semi-lunar valves that prevent backflow 
of the lymph through the lumen of the lymphangions. 
Synergistic functioning of these two types of valves 
coupled with rhythmic contraction and relaxation of the 
smooth muscular layer of the lymphangions produces a 
motion and forces lymph from one lymphangion to the 
next. The lymphangions finally merge into afferent lymph 
vessels, which subsequently drain into the subcapsular 
sinus of various lymph nodes located throughout the body. 
  Recent studies suggest that the major source of lympha-
tic endothelial cells during development in mammals is 
generated through trans-differentiation from embryonic 
veins (5). During differentiation into lymphatic 
endothelial cells (LECs), prospero-related homeodomain 
transcription factor (Prox1) is essential for lymphatic-
endothelium-specific programming. Prox1 downregulates 
blood markers and promotes expression of vascular 
endothelial growth factor receptor (VEGFR)-3, which is 
important for LEC survival, migration, and proliferation. 
LECs then start to bud by following the gradient of a 
VEGFR-3 ligand, VEGFC (6). As a selective marker 
for lymph capillary endothelial cells, lymphatic vessel 
endothelium hyaluronan receptor (LYVE-1) has been 
utilized commonly to study the lymph vessel network. In 
addition, to visualize the lymphatic vessels in vivo, Prox1-
fluorescently-labeled transgenic animals that expresses 
GFP or tdTomato driven by the promoter of Prox1, a 
master regulator in lymphatic development, have been 
broadly used. Adult lymphatic vessels could be easily 
detected in peripheral tissue such as the trachea, skin, ear, 
intestine, and diaphragm (7). Such identification, in recent 
decades, of several key regulators and markers specific to 
LECs has accelerated findings that LECs actively interact 
with other cells.
lymPhaTIC vessels fROm PeRIPheRal TIssUes 
TO lymPh NODes
Together with macrophages and monocytes, dendritic 
cells (DCs) belong to the mononuclear phagocyte 
system. Both macrophages and DCs are in close contact 
with LECs for adaptive immunity and tolerance. Early 
reports showed that lymph-borne antigens arrive in 
lymph nodes only a few minutes after subcutaneous 
injection (8). As a secondary lymphoid organ, a lymph 
node is the main place to activate an immune response as 
well as the terminal end of the lymphatic system before 
the lymph fluid is drained into the circulatory system. 
Before draining into the vein of the circulatory system, 
the lymph fluid is screened for foreign antigens in the 
lymph node through the efferent lymphatic vessels. 
Strategically positioned along lymphatic vessels of the 
subcapsular sinus, lymph node-resident macrophages 
play a key role in filter stations, preventing systemic 
pathogen dissemination (9). Furthermore, the lymphatic 
vasculature system supports immune cell migration as 
well as lymph fluid circulation from a tissue to lymph 
nodes. Lymphatic capillaries and collecting vessels 
require differential several steps to move DCs into a 
lymph node (1). By highly expressing CCL19 and CCL21, 
lymphatic capillaries attract DCs expressing CC-chemo-
kine receptor 7 (CCR7). In addition to chemokine gra-
dient-dependent migration, it was proposed that their 
migration is dependent on amoeboid movement rather 
than integrin-dependent movement in a steady state (2,10). 
In a pathological condition, dendritic cells are activated 
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by pathogen-associated molecular patterns (PAMPs) 
such as Toll-like receptors (TLRs), and their movement 
depends on integrins such as ICAM-1 and VCAM-1. 
Once DCs enter the lymphatic capillaries from peripheral 
tissues, DCs crawl onto LECs toward the lymphatic 
collecting vessels by taking advantage of binding CCR7 
to its ligands CCL19 and CCL21. CCL21 deficiency 
completely impairs the DC migration, suggesting that 
intra-lymphatic migration of DCs is dependent on the 
CCL21 chemotactic gradient (11). Upon arrival into the 
lymphatic collecting vessels, lymphatic fluid force leads 
passive transport of DCs into the subcapsular sinus of a 
lymph node. In lymphatic collecting vessels, the direction 
and rate of lymphatic flow are regulated by lymphatic 
valves and lymphatic muscle. Lymphatic muscle surroun-
ding LECs contributes to the contraction of lymphatic 
collecting vessels by regulating lymph pressure (12). 
In addition to the lymphatic valve and muscle, DCs 
surrounding the lymphatic collecting vessels affect the 
permeability of lymphatic collecting vessels by interacting 
with LECs. In the absence of CCR7, the interaction 
between DCs and the endothelial cells of lymphatic 
collecting vessels is highly reduced because of the loss 
of CCR7–CCL21 interaction (12). Lymphatic collecting 
vessels show various phenotypes in CCR7-deficient mice. 
First, collagen deposition is dramatically increased on the 
collecting vessel wall, resulting in fibrosis. Second, the 
permeability of collecting vessels is significantly elevated 
in CCR7-deficient mice, implying that CCR7+ DCs 
control lymphatic permeability. Lastly, the removal of a 
lymph-derived tracer is altered in CCR7-deficient mice, 
suggesting that lymphatic transport is associated with DCs. 
In addition to the regulation of lymphatic permeability, 
lymphatic collecting vessels seem to orchestrate a local 
immune response by adipose tissue myeloid cells inclu-
ding DCs (13). Injected into skin, fluorescent antigen 
tracers are delivered to CD11c+ MHCII+ DCs in adipose 
tissue through the collecting lymphatic vessels, suggesting 
that these DCs sample lymph-borne antigens during local 
inflammation and T-cell infiltration (Fig. 1). In addition, 
CD11b+ Gr1+ myeloid cells suppress the contraction of 
lymphatic collecting vessels in an inflammatory condition 
(14). Overall, lymphatic flow in lymphatic collecting 
vessels is tightly regulated by spatially distinct LECs 
and by the cross-talk between LECs and tissue-resident 
DCs. Nonetheless, further research is necessary on the 
molecular mechanism explaining how peripheral tissue 
resident DCs regulate LECs.
The ROle Of lymPhaTICs IN The RegUlaTION Of 
TOleRaNCe 
As discussed above, the lymphatic vasculature provides 
routes for DC and lymphocyte migration into and out of a 
lymph node. LECs control these processes by expression 
of chemokines and adhesion molecules. LECs also can 
express immunosuppressive factors such as TGF-b, 
indoleamine-2,3-dioxygenase, and nitric oxide to maintain 
peripheral tolerance to self-antigens in lymph (15,16) 
Figure 1. Schematic models of lymphatic flow. (A) Activated DCs can enter the lymphatic capillaries in a CCR7-dependent but integrin-independent 
manner. Other molecules such as proteins and lipids can be absorbed in lymphatic capillaries. (B) In capillaries, lymphatic endothelial cells drive 
DCs toward lymphatic collecting vessels by forming chemokine gradients. (C) Once DCs enter the collecting vessels, the interaction of adipose 
myeloid cells and collecting endothelial cells controls lymphatic flow, which facilitates passive transport of DCs into a lymph node.
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In this regard, LECs participate in the immune response 
by releasing an appropriate chemokine and cytokines in 
response to environmental changes in peripheral tissues. 
Emerging studies demonstrate that lymphatic vessels 
exhibit tolerogenic potential by regulating T-cell fate and 
function in immunity. First, it has been shown that LECs 
can directly dampen DC maturation (17), in turn reducing 
their ability to activate effector T cells. Second, LECs 
constitutively express and present a self-antigen on MHC 
class I molecules to delete autoreactive T cells and thus 
help maintain peripheral tolerance to these self-antigens 
(18). LECs can drive deletional tolerance of naïve CD8 
T cells without costimulatory molecules necessary to 
activate effector T cells, and instead express the inhibitory 
ligand PD-L1 (19). Third, it is now known that LECs 
can actively scavenge exogenous lymph-borne antigens 
and process them for cross-presentation on MHC class 
I molecules (20,21). In summary, LECs may potentially 
help to maintain tolerogenic pressure by presenting both a 
scavenged and endogenous antigen.
The ROle Of lymPhaTICs IN INflammaTION
The inflammation process is accompanied by several 
localized or systemic events such as vascular responses, 
migration and activation of leukocytes, and systemic 
inflammatory response syndrome. Additionally, lymphan-
giogenesis frequently occurs during inflammation. To 
relieve the hostile microenvironment causing inflam-
mation, a harmful antigen and debris should be removed 
by drainage of excessive interstitial fluid through lym-
phatic vasculature. Upon initiation of inflammation, the 
lymphatic system is activated, and both the lymphatic 
vessels in peripheral tissues and inside a lymph node 
expand in response to inflammation. Accumulating 
evidence suggests that inflammation-associated lymphan-
giogenesis is not an endpoint phenotype of inflammation 
but rather a type of dynamic and active reaction that can 
control the inflammatory response or tissue repair (22). 
Lymphatic vessels newly generated by inflammation 
play a role in regulation of repair of a damaged tissue 
(23) and macrophage/DC recruitment, which is critical 
for pathogen clearance (24). The infiltrating monocyte-
derived macrophages in the lymphatic vessel induce 
lymphangiogenesis by secreting lymphangiogenic growth 
factors (VEGF) (25). These ligands (VEGF) secreted 
from infiltrated macrophages could be major mediators of 
pathogen clearance and inflammation resolution through 
profound expansion of lymphatic vessels, enhanced 
lymph flow, and mobilization of inflammatory cells from 
the inflamed skin to the draining lymph nodes (26). Such 
interactions between lymphatic vessels and immune 
cells contribute to the immune system’s response to in-
flammatory stimuli. Consequently, the inflammation-
associated lymphangiogenesis may directly influence 
the degree of mucosal edema and leukocyte infiltration. 
Impairment of lymphatic drainage caused by infection, 
surgery, or trauma results in lymphedema with swelling of 
limbs or other peripheral mucosal tissues. The associated 
lymphostasis causes persistence and accumulation of 
the antigen, foreign material, and immune complexes 
in the interstitium, which can cause chronic localized 
inflammation and fibrosis. This chronic inflammation 
also attenuates lymphatic contraction, hindering lympha-
tic flow to the lymph node and disrupting the trafficking 
of lymphocytes to the lymph node. Thus, lymphedema 
cumulatively results in a region of local immune suppres-
sion (27). Accordingly, altered immunity has been re-
ported in lymphedema, highlighting the importance of 
lymphatic pathways in adaptive immune responses in 
a variety of pathologies. Overall, the role of lymphatic 
vessels in the modulation of the immune system in terms 
of response to inflammation caused by environmental 
stimulation of peripheral tissues is crucial for homeostasis. 
  In the detailed molecular mechanism of lymphangio-
genesis, pro-lymphangiogenic signaling pathways, 
among which the VEGF-C and D/VEGFR3 axis is 
the best characterized, are activated by inflammatory 
stimuli. Inhibition of the VEGF-C/VEGFR3 axis sup-
presses lymphangiogenesis and relieves the severity of 
inflammatory symptoms in rheumatoid arthritis and LPS-
induced acute inflammation (26). In addition, VEGF-A 
either promotes lymphatic vasculature formation via 
activation of VEGFR2 in repair associated lymphan-
giogenesis (28). However, T cells negatively regulate 
lymphatic vessels through T helper 1 (Th1) or Th2 
cytokines (anti-lymphangiogenic factors) (29). During 
the acute stage of inflammation, the pro-lymphangiogenic 
factors usually dominate, in which case, finally, lymphatic 
vessels are amplified. As inflammation resolves, the anti-
lymphangiogenic effect increases. The balance between 
the pro-lymphangiogenic factors (VEGF-A, VEGF-C, 
VEGF-D) and anti-lymphangiogenic factors (Th1: IFN-g, 
Th2: IL-4, IL-13) produced by immune cells influences 
the actual response of lymphatic vessels to inflammatory 
stimuli. Accordingly, lymphatic vessels either grow or 
regress. In the clinic, treatments for lymphedema include 
lymphatic compression, exercise, or surgical interventions 
to improve the lymph flow. Thus, these research studies 
Lymphatic Vasculature and Immune Modulation
IMMUNE NETWORK Vol. 17, No. 1: 68-76, February, 201772
suggest that targeting the anti-lymphangiogenic factors 
alone or in conjunction with other therapeutic approaches 
could be a new strategy for treating lymphedema caused 
by infection or environmental stress. 
lymPhaTIC vessels IN mUCOsal TIssUes 
Lymphatics are prevalent in mucosal tissues that come 
into direct contact with the external environment. In 
this context, depending on the tissue environmental 
stimulation, LECs have distinct phenotypic and functional 
characteristics (30). Additionally, lymphatic vessels, 
which continuously transport circulating antigens, may 
represent an important line of defense against pathogens. 
It is striking that NF-kB activity is constitutive in 
lymphatics of respiratory and gastrointestinal systems 
that are in direct contact with external environment (31). 
In mice with a reporter gene for NF-kB activity (kB-
lacZ), NF-kB is constitutively active in the lymphatic 
endothelium rather than in blood vessels in the uterus, 
intestine, and airways under normal conditions (31). 
These observations challenge the notion that the recogni-
tion of externally stimulated PAMPs by TLRs in lym-
phatic vessels results in the activation of transcription 
factor NF-kB as part of innate immunity. Several studies 
have revealed that LECs express large amounts of various 
TLRs and activate NF-kB by LPS and other TLR ligands 
for induction of inflammatory lymphangiogenesis (32). 
Therefore, LECs may have tissue-specific phenotypes and 
functions depending on the tissue environment in which 
they are located.
gastrointestinal tract
Lymphatics in the gastrointestinal (GI) tract perform 
important mucosal immune functions in acquired im-
munity and tolerance because the GI tract is widely 
exposed to commensal bacteria. Lymphatic capillaries in 
the center of intestinal villi, called lacteal, are important 
for the absorption of nutrients as well as immune cell 
trafficking into mesenteric lymph nodes. The intestine 
contains three layers of lymphatics, including (in the 
direction from the luminal surface to the serosal surface): 
the lacteals in the villi, a submucosal lymphatic network, 
and a lymphatic network in the smooth muscle layer (Fig. 
2). The lacteals connect with the submucosal lymphatic 
network at the base of the villi. A recent study revealed 
that lacteal longitudinally has been surrounded by bundles 
of smooth muscles and consequently are responsible 
for spontaneous contractile dynamics (33). This finding 
indicates that even though the lacteal is located at the end 
of peripheral tissue as a capillary, the lacteal has a unique 
tissue-specific lymphatic system that does not serve as a 
passive conduit but as an active pump, which transports 
Figure 2. The small-intestine lymphatic system. The small intestine contains two independent lymphatic networks that drain into a common network 
of collecting lymphatics. The lacteals, draining individual villi, connect with a network of lymphatics within the mucosal layer to form one distinct 
network (red), while the lymphatics of the mucosal muscle layer form another network (blue). Injection of tracers into these networks reveals free 
flow within each network but no exchange between networks. Both networks drain into contractile collecting lymphatics (yellow) located at the 
mesenteric border and outside of the intestine.
Lymphatic Vasculature and Immune Modulation
http://immunenetwork.org 73
lipids. Using conditional ablation of Lyve-1+ lacteals in 
the small intestine, it was revealed that the disappearance 
of lacteals gives rise to the distortion of blood capillaries 
and the whole architecture of villi, which allows for a 
massive invasion of intestinal pathogens without a barrier 
and immune surveillance and subsequently causes severe 
inflammation in the intestine (34). Likewise, intestinal 
lacteals contribute to the defense system against mucosal 
pathogens in the lumen. 
  Intestinal lymphatics are involved in a variety of disease 
processes such as congenital malformations resulting in 
pathological dilation of lymphatic vessels (lymphangiec-
tasia) and inflammation with dynamic lymphatic growth 
and remodeling (35). Increased lymphatics have are seen 
in ulcerative colitis (UC) along with lymphangiectasia, 
particularly in areas with epithelial dysplasia (36). While 
lymphangiogenesis and lymphangiectasia are also found 
in ileal and colonic Crohn’s disease (CD) (37), these 
observations imply a more direct correlation between lym-
phatics and the colitis pathogenesis. These studies showing 
a role of lymphatics in inflammatory bowel disease 
suggest that understanding the cause and consequences 
of lymphangitis could be a key to understanding Crohn’s 
disease pathogenesis. 
  The intestinal environmental factors selectively affect 
the development of the intestinal lymphatic system. 
Fasting-induced adipose factor (Fiaf) also called angio-
poietin-like protein 4 (Angptl4) is produced in the intes-
tine and regulates the expression of Prox1, a transcription 
factor crucial for lymphangiogenesis (38). Deletion of 
the fiaf gene results in failure of blood and lymphatic 
vasculature partitioning in the small intestine. This 
finding emphasizes the uniqueness of the intestinal 
lymphatic system related to its role as a pathway for 
nutrient transport. Accumulating recent discoveries about 
the intestinal lymphatic vasculature in the GI tract offer 
convincing evidence that the lymphatic system in the 
intestinal mucosa is affected by and directly contributes to 
the pathogenesis of intestinal diseases. 
Respiratory tract
In the steady state, lymphatic vessels of the respiratory 
tract optimize and facilitate the entrance of immune 
cells and interstitial fluid. As described above, the initial 
lymphatic capillaries are discontinuous button-like 
junctions, through which inflammatory cells frequently 
pass. Interestingly, the airway infected with Mycoplasma 
pulmonis shows growing lymphatic sprouts, which 
have a continuous junctional pattern, zippers instead 
of buttons (39). Such remodeling of the lymphatic 
vessels makes them less permeable and contributes 
to impaired fluid clearance and mucosal edema. After 
inflammation is resolved, the number of the lymphatic 
sprouts is decreased, and their microstructure again 
consists of buttons (40). Chronic inflammatory diseases 
involving the respiration system may be accompanied 
by significant structural alterations of lymphatic vessels, 
which probably are irreversible changes that are resistant 
to lymphatic-modulating treatments. When lymphan-
giogenesis is impaired, airway inflammation may lead 
to bronchial lymphedema and exaggerated airflow obs-
truction. Impaired drainage of the edema fluid may be 
expected to lead to airway wall thickening, reduced wall 
compliance, and narrowing of the airway lumen. Cor-
rection of defective lymphangiogenesis may benefit 
the treatment of asthma and other inflammatory airway 
diseases (41). Consistent with these consequences of im-
paired lymphangiogenesis is the finding that blocking 
of the lymphatic transport from inflamed rabbit ear 
skin may exacerbate local edema and eventually lead to 
necrosis (42). Thus, if lymphangiogenesis is impaired in 
inflamed airways, restoration of lymphangiogenesis may 
complement conventional therapies for inflammatory 
airway diseases. 
CONClUsIONs
The lymphatic vasculature system, which has a specia-
lized network of structures to transport tissue fluid and 
materials such as proteins and lipids to blood vasculature, 
closely interacts with distinct immune cells for execution 
of specific functions. For efficient flow from lymphatic 
capillaries to lymph nodes, LECs interact with myeloid 
cells in adipose tissue to regulate lymphatic permeability. 
For an immune reaction, activated immune cells such as 
DCs and memory T cells can actively or passively migrate 
from the tissue to lymph nodes through lymphatic vessels. 
The latter participate in the immune response by releasing 
an appropriate chemokine and cytokines in response to 
environmental changes in peripheral tissues. Because 
lymphatic vasculature is widespread throughout the 
whole body including the brain, it has been proposed that 
lymphatic vasculature maintains the peripheral tolerance 
in a steady state. In a pathological condition, however, 
inflammation frequently induces lymphangiogenesis, 
resolving inflammation by recruiting additional immune 
cells. Although VEGF-C and VEGFR3 have been mainly 
studied as key pro-lymphangiogenesis regulatory factors, 
it is still unknown whether other factors are involved 
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in a tissue-dependent manner. In particular, intestinal 
lymphatic capillaries are constantly exposed to the 
commensal microbiota and are important for immune-
cell migration as well as nutrient absorbance. Therefore, 
it is necessary to conduct a molecular mechanistic study 
on the interaction between the commensal microbiota 
and lacteal development. Furthermore, the correlation 
between the lymphatic system and immune cells can be 
considered a therapeutic target in disease models such as 
Crohn’s disease and ulcerative colitis in future studies. 
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